Cr2O3/Al-Al2O3 composite catalysts for hydrocarbons dehydrogenation prepared from aluminum nanopowder

Aluminum nanopowder (10–150 nm) was treated hydrothermally in mild conditions (60–95 °C, at atmospheric pressure), and an aluminum-alumina composite with high porosity and specific surface area was obtained. Cr2O3/Al-Al2O3 catalysts were prepared using the aluminum-alumina composite by impregnation techniques and tested in dehydrogenation of C4-hydrocarbons. It was shown that aluminum-alumina composites had high chemical and phase purity, specific surface area of 150–350 m2/g and the average pore size of 8–13 nm, that is favorable for application as support for catalysts. Cr2O3/Al-Al2O3 catalysts had high activity and selectivity in dehydrogenation of n- and i-butane (conversion of 44–80 mol.% and selectivity >85% at temperatures of 540–610 °C), that is comparable ones for commercial catalysts for CATOFIN, STAR processes

Cr2O3/Al-Al2O3 composite catalysts for hydrocarbons dehydrogenation prepared from aluminum nanopowder

Aluminum nanopowder (10–150 nm) was treated hydrothermally in mild conditions (60–95 °C, at atmospheric pressure), and an aluminum-alumina composite with high porosity and specific surface area was obtained. Cr2O3/Al-Al2O3 catalysts were prepared using the aluminum-alumina composite by impregnation techniques and tested in dehydrogenation of C4-hydrocarbons. It was shown that aluminum-alumina composites had high chemical and phase purity, specific surface area of 150–350 m2/g and the average pore size of 8–13 nm, that is favorable for application as support for catalysts. Cr2O3/Al-Al2O3 catalysts had high activity and selectivity in dehydrogenation of n- and i-butane (conversion of 44–80 mol.% and selectivity >85% at temperatures of 540–610 °C), that is comparable ones for commercial catalysts for CATOFIN, STAR processes

Thermally-activated Al(OH)3: phase transformations and porosity

Thermochemically activated aluminum trihydroxide (Al (OH)3) is an important intermediate for ceramics, construction materials, catalysts, etc. Functional properties of materials based on Al (OH)3 depend on its phase composition and porosity. A series of thermochemically activated Al (OH)3 calcined at temperatures from 120 to 800 °C were studied by low-temperature N2 sorption, XRD and thermal analysis. It was shown that transformation of gibbsite to boehmite occurs below 300 °C and is accompanied by increasing of specific surface area and pore volume. Transformation of boehmite to γ-Al2O3 proceeds above 400 °C. The sample calcined at 500 °C was shown to consist of monophase γ-Al2O3 with specific surface area of 206 m2/g and pore volume of 0.55 cm3/g

Thermally-activated Al(OH)3: phase transformations and porosity

Thermochemically activated aluminum trihydroxide (Al (OH)3) is an important intermediate for ceramics, construction materials, catalysts, etc. Functional properties of materials based on Al (OH)3 depend on its phase composition and porosity. A series of thermochemically activated Al (OH)3 calcined at temperatures from 120 to 800 °C were studied by low-temperature N2 sorption, XRD and thermal analysis. It was shown that transformation of gibbsite to boehmite occurs below 300 °C and is accompanied by increasing of specific surface area and pore volume. Transformation of boehmite to γ-Al2O3 proceeds above 400 °C. The sample calcined at 500 °C was shown to consist of monophase γ-Al2O3 with specific surface area of 206 m2/g and pore volume of 0.55 cm3/g

Insights into formation of Pt species in Pt/CeO2 catalysts: Effect of treatment conditions and metal-support interaction

The features of the formation of Pt species on the CeO2 surface from adsorbed [PtCl6-yOy] complexes in Pt/CeO2 catalysts depending on the Pt content (0.5, 1.0 and 2.0 wt.%) and treatment conditions (direct Pt precursor reduction, oxidative and reductive treatments) are studied by XRD, CO pulse chemisorption, H2-TPR, UV–vis DRS, and Raman spectroscopy. The temperature of oxidative decomposition of the Pt precursor is shown to be the key factor that defines the state and size of the Pt species formed. High pretreatment temperature (500 °C) provides Pt incorporation into ceria lattice and yields smaller Pt particles after reduction providing strong Pt–CeO2 interaction, while the reduction of the samples dried at 120 °C results in the pronounced agglomeration of the formed Pt species to yield Pt particles weakly bonded with the ceria

Targeted Blood Plasma Proteomics and Hemostasis Assessment of Post COVID-19 Patients with Acute Myocardial Infarction

The molecular mechanisms underlying cardiovascular complications after the SARS-CoV-2 infection remain unknown. The goal of our study was to analyze the features of blood coagulation, platelet aggregation, and plasma proteomics in COVID-19 convalescents with AMI. The study included 66 AMI patients and 58 healthy volunteers. The groups were divided according to the anti-N IgG levels (AMI post-COVID (n = 44), AMI control (n = 22), control post-COVID (n = 31), and control (n = 27)). All participants underwent rotational thromboelastometry, thrombodynamics, impedance aggregometry, and blood plasma proteomics analysis. Both AMI groups of patients demonstrated higher values of clot growth rates, thrombus size and density, as well as the elevated levels of components of the complement system, proteins modifying the state of endothelium, acute-phase and procoagulant proteins. In comparison with AMI control, AMI post-COVID patients demonstrated decreased levels of proteins connected to inflammation and hemostasis (lipopolysaccharide-binding protein, C4b-binding protein alpha-chain, plasma protease C1 inhibitor, fibrinogen beta-chain, vitamin K-dependent protein S), and altered correlations between inflammation and fibrinolysis. A new finding is that AMI post-COVID patients opposite the AMI control group, are characterized by a less noticeable growth of acute-phase proteins and hemostatic markers that could be explained by prolonged immune system alteration after COVID-19

CD44 Expression in Renal Tissue Is Associated with an Increase in Urinary Levels of Complement Components in Chronic Glomerulopathies

It is suggested that activated CD44+ cells play a profibrogenic role in the pathogenesis of active glomerulopathies. Complement activation is also involved in renal fibrogenesis. The aim of the study was to evaluate the role of the activation of CD44+ cells in the kidney tissue and complement components’ filtration to the urine as factors of renal tissue fibrosis in patients with glomerulopathies. In total, 60 patients with active glomerulopathies were included in our study: 29 patients with focal segmental glomerulosclerosis (FSGS), 10 patients with minimal change disease (MCD), 10 patients with membranous nephropathy (MN), and 11 patients with IgA nephropathy. The immunohistochemical peroxidase method was used to study the expression of CD44+ in kidney biopsies. Components of complement were analyzed in urine by the multiple reaction monitoring (MRM) approach using liquid chromatography. Strong CD44 expression was noted predominantly in PEC and mesangial cells (MC) in patients with FSGS, and to a lesser extent, in patients with MN and IgA nephropathy, and it was absent in patients with MCD. Expression of profibrogenic CD44+ in glomeruli correlated with the levels of proteinuria and complement C2, C3, and C9 components, and CFB and CFI in urine. The CD44+ expression scores in the renal interstitium correlated with the level of C3 and C9 components of complement in the urine and the area of tubulo-interstitial fibrosis. The strongest expression of CD44+ was found in the glomeruli (MC, PEC, and podocytes) of patients with FSGS compared with other glomerulopathies. The CD44 expression score in the glomeruli and interstitium is associated with high levels of complement components in the urine and renal fibrosis

Hepatoprotective Activity of Lignin-Derived Polyphenols Dereplicated Using High-Resolution Mass Spectrometry, In Vivo Experiments, and Deep Learning

Chronic liver diseases affect more than 1 billion people worldwide and represent one of the main public health issues. Nonalcoholic fatty liver disease (NAFLD) accounts for the majority of mortal cases, while there is no currently approved therapeutics for its treatment. One of the prospective approaches to NAFLD therapy is to use a mixture of natural compounds. They showed effectiveness in alleviating NAFLD-related conditions including steatosis, fibrosis, etc. However, understanding the mechanism of action of such mixtures is important for their rational application. In this work, we propose a new dereplication workflow for deciphering the mechanism of action of the lignin-derived natural compound mixture. The workflow combines the analysis of molecular components with high-resolution mass spectrometry, selective chemical tagging and deuterium labeling, liver tissue penetration examination, assessment of biological activity in vitro, and computational chemistry tools used to generate putative structural candidates. Molecular docking was used to propose the potential mechanism of action of these structures, which was assessed by a proteomic experiment

Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease

Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine of the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score—depending on the proteinuria level, the third score—resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more—in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I